[{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"583d3d4e-954b-4daf-9f41-90e56eda49dd","acronym":"DYNASTY-Breast02","url":"https://clinicaltrials.gov/study/NCT06018337","created_at":"2023-08-30T14:09:02.590Z","updated_at":"2025-02-25T16:40:10.354Z","phase":"Phase 3","brief_title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","source_id_and_acronym":"NCT06018337 - DYNASTY-Breast02","lead_sponsor":"DualityBio Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)"],"overall_status":"Recruiting","enrollment":" Enrollment 532","initiation":"Initiation: 01/18/2024","start_date":" 01/18/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-06"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2025-02-25T16:45:09.442Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 12/04/2025","study_completion_date":" 12/04/2025","last_update_posted":"2025-02-05"},{"id":"7b8a02fc-93ba-4510-a730-5331f3179340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04147819","created_at":"2021-01-18T20:19:04.190Z","updated_at":"2025-02-25T17:11:00.786Z","phase":"Phase 1","brief_title":"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein","source_id_and_acronym":"NCT04147819","lead_sponsor":"Bayer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY2701439 • BAY2701438"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2024-09-27"},{"id":"de32242c-e2ef-4e4e-af03-36f807029c84","acronym":"KL264-01","url":"https://clinicaltrials.gov/study/NCT04152499","created_at":"2021-01-18T20:16:04.885Z","updated_at":"2025-02-25T16:25:32.908Z","phase":"Phase 1/2","brief_title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies","source_id_and_acronym":"NCT04152499 - KL264-01","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • HER-2 • MSI • BRCA • TACSTD2","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation","tags":["EGFR • HER-2 • MSI • BRCA • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/16/2026","study_completion_date":" 07/16/2026","last_update_posted":"2024-06-24"},{"id":"03bc5e50-b478-4d68-87f2-dc93e0cc73f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06031584","created_at":"2023-09-11T16:10:34.582Z","updated_at":"2024-07-02T16:35:15.514Z","phase":"Phase 1/2","brief_title":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","source_id_and_acronym":"NCT06031584","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab brengitecan (BL-M07D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-08"},{"id":"3a7e9555-d637-48a3-b946-efc68b5e6c6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05945732","created_at":"2023-07-14T18:08:57.668Z","updated_at":"2024-07-02T16:35:15.810Z","phase":"","brief_title":"DESTINY Breast Respond HER2-low Europe","source_id_and_acronym":"NCT05945732","lead_sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 1350","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-03-07"},{"id":"dd93d217-a333-439e-aa8e-029a17abbff7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06105008","created_at":"2023-10-27T17:14:07.187Z","updated_at":"2024-07-02T16:35:18.462Z","phase":"Phase 2","brief_title":"Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT06105008","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2024","start_date":" 12/20/2024","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-02-21"},{"id":"c470b529-9dfd-48a9-8efd-1f3df1255e9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05461768","created_at":"2022-07-18T14:01:36.397Z","updated_at":"2024-07-02T16:35:21.563Z","phase":"Phase 1","brief_title":"A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT05461768","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab brengitecan (BL-M07D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-01-31"},{"id":"dad3c06e-1069-4af6-84ff-6a9a73aa0a3a","acronym":"DS8201-A-J101","url":"https://clinicaltrials.gov/study/NCT02564900","created_at":"2021-01-17T17:11:34.411Z","updated_at":"2025-02-25T15:06:49.980Z","phase":"Phase 1","brief_title":"Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors","source_id_and_acronym":"NCT02564900 - DS8201-A-J101","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 mutation • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 mutation • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 292","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2024-01-22"},{"id":"435158fa-5968-4e80-bf8f-2f21ac9fff3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05911958","created_at":"2023-06-22T20:09:27.571Z","updated_at":"2024-07-02T16:35:25.706Z","phase":"Phase 2","brief_title":"A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer","source_id_and_acronym":"NCT05911958","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2023-12-20"},{"id":"c585fc8f-5ca9-4ccf-af6f-4cb8e94745d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861895","created_at":"2023-05-17T14:05:15.792Z","updated_at":"2024-07-02T16:35:26.123Z","phase":"Phase 1","brief_title":"A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors","source_id_and_acronym":"NCT05861895","lead_sponsor":"HighField Biopharmaceuticals Corporation","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HF158K1"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 04/23/2025","primary_completion_date":" 04/23/2025","study_txt":" Completion: 12/22/2025","study_completion_date":" 12/22/2025","last_update_posted":"2023-12-15"},{"id":"0b41fdfe-9a1f-478b-aa60-e114706459cf","acronym":"RosHER","url":"https://clinicaltrials.gov/study/NCT05217381","created_at":"2022-02-05T18:28:12.227Z","updated_at":"2025-02-25T15:00:15.610Z","phase":"","brief_title":"Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status","source_id_and_acronym":"NCT05217381 - RosHER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 positive + HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 positive + HER-2 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 18533","initiation":"Initiation: 02/22/2022","start_date":" 02/22/2022","primary_txt":" Primary completion: 09/20/2023","primary_completion_date":" 09/20/2023","study_txt":" Completion: 09/20/2023","study_completion_date":" 09/20/2023","last_update_posted":"2023-09-25"},{"id":"aedd2a0c-1dd3-44bd-80bc-7798661eda8a","acronym":"DEBBRAH","url":"https://clinicaltrials.gov/study/NCT04420598","created_at":"2021-01-18T21:18:05.619Z","updated_at":"2024-07-02T16:35:37.867Z","phase":"Phase 2","brief_title":"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease","source_id_and_acronym":"NCT04420598 - DEBBRAH","lead_sponsor":"MedSIR","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2023-09-07"},{"id":"e9088b3f-0868-41a9-b517-cccbd53cad7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05845138","created_at":"2023-05-06T15:04:34.884Z","updated_at":"2024-07-02T16:35:41.287Z","phase":"Phase 1/2","brief_title":"A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.","source_id_and_acronym":"NCT05845138","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-01"},{"id":"4354679e-5391-465c-8311-51adc5b55004","acronym":"Conerstone3","url":"https://clinicaltrials.gov/study/NCT05771584","created_at":"2023-03-16T14:02:37.509Z","updated_at":"2024-07-02T16:35:42.388Z","phase":"Phase 2","brief_title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","source_id_and_acronym":"NCT05771584 - Conerstone3","lead_sponsor":"Aston Sci. Inc.","biomarkers":" HER-2 • CD8 • CD4","pipe":" | ","alterations":" HER-2 overexpression • HER-2 underexpression","tags":["HER-2 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AST-301 • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/04/2023","start_date":" 07/04/2023","primary_txt":" Primary completion: 10/15/2023","primary_completion_date":" 10/15/2023","study_txt":" Completion: 06/15/2026","study_completion_date":" 06/15/2026","last_update_posted":"2023-07-20"},{"id":"4da7b4b3-e523-424f-aa82-d7ce31d2f800","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861635","created_at":"2023-05-17T14:05:12.243Z","updated_at":"2024-07-02T16:35:47.760Z","phase":"Phase 4","brief_title":"The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression","source_id_and_acronym":"NCT05861635","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 expression • HER-2 underexpression • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 expression • HER-2 underexpression • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-05-17"},{"id":"cb4ebc1f-10ef-4c5a-8b79-4f2454bd313d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05466786","created_at":"2022-07-20T12:56:23.701Z","updated_at":"2024-07-02T16:36:07.127Z","phase":"","brief_title":"Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer","source_id_and_acronym":"NCT05466786","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 335","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2022-07-20"},{"id":"689c6049-2a2f-4a74-9a8b-92d262cf6cc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05018676","created_at":"2021-08-24T11:52:57.776Z","updated_at":"2024-07-02T16:36:11.538Z","phase":"Phase 2","brief_title":"ARX788 in Breast Cancer With Low Expression of HER2","source_id_and_acronym":"NCT05018676","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anvatabart opadotin (JNJ-0683)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2022-04-25"},{"id":"b414fa64-f178-4986-a5ff-2c88f3a21278","acronym":"","url":"https://clinicaltrials.gov/study/NCT04828616","created_at":"2021-04-02T11:53:35.097Z","updated_at":"2024-07-02T16:36:32.421Z","phase":"Phase 2","brief_title":"Study of DP303c Injection in Patients With Advanced Ovarian Cancer","source_id_and_acronym":"NCT04828616","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab envedotin (DP303c)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2021-04-02"},{"id":"6979cef1-b4b7-443c-8e4f-a64b76aeed5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826107","created_at":"2021-04-01T16:52:31.994Z","updated_at":"2024-07-02T16:36:32.510Z","phase":"Phase 2","brief_title":"Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer","source_id_and_acronym":"NCT04826107","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab envedotin (DP303c)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-04-01"},{"id":"f0e93ff9-0d1a-45ea-9bbd-11ac3d3c0752","acronym":"NATURE","url":"https://clinicaltrials.gov/study/NCT02725541","created_at":"2021-01-18T13:20:28.303Z","updated_at":"2024-07-02T16:37:29.136Z","phase":"Phase 2","brief_title":"Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer","source_id_and_acronym":"NCT02725541 - NATURE","lead_sponsor":"Jenny C. Chang, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2016-09-14"}]